LENZ Therapeutics, Arrotex Ink Commercialization Deal for VIZZ in Australia and New Zealand

Published on June 26, 2026
SAN DIEGO and MELBOURNE, Australia—LENZ Therapeutics, Inc., (Nasdaq: LENZ) a pharmaceutical company focused on commercializing VIZZ (aceclidine ophthalmic solution) 1.44%, and Arrotex Pharmaceuticals Pty Ltd. have announced an exclusive licensing and commercialization agreement under which Arrotex will register and commercialize VIZZ eye drops for the treatment of presbyopia in Australia and New Zealand. The U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in July 2025, and VIZZ has been commercially available in the U.S. since October 2025.
Continue reading on website
Other news

Optos Celebrates Milestone of 30,000 Retinal Imaging Devices Installed Worldwide

June 26, 2026
DUNFERMLINE, U.K.—Optos PLC, a leader in retinal imaging technology, announced it has achieved the global milestone of 30,000 devices installed worldwide. For more than 30 years, “Optos has played a critical role in progressing retinal imaging and supporting improved patient care worldwide,” the company stated. As part of this milestone, Optos also recognized Radiance Eye Care, as its 30,000th cus

Haag-Streit USA and Casey Eye Institute Partner to Advance Perimetry Program

June 26, 2026
MASON, Ohio—Haag-Streit USA, a leading U.S. distributor of ophthalmic devices, has announced a new strategic initiative in collaboration with the Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU). The initiative aims to enhance training, consultation and research in clinical perimetry by establishing a comprehensive educational program designed by the institute’s Casey Visual